Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cognitive Function, Preclinical Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Predicting Pre-dementia

NCT07516119
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
Interventions
Not listed
Lead sponsor
Prevention Research Consortium Corp.
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 23, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

NCT04928976
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 23, 2026, 9:48 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jul 23, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

NCT01592552
View directory record Official record
Conditions
Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Sherman Oaks, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 23, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Measures of CSF Clearance in Preclinical Alzheimer's Disease

NCT03663387
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 23, 2026, 9:48 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Jul 23, 2026, 9:48 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT03131453
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CNP520 50mg, CNP520 15mg, Matching placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
1,145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
95
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jul 23, 2026, 9:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

NCT02045056
View directory record Official record
Conditions
Preclinical Alzheimer's Disease
Interventions
Gemfibrozil, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 23, 2026, 9:48 PM EDT
Not listed No phase listed Observational

Evidence Amyloid Scan EEG Study

NCT03644043
View directory record Official record
Conditions
Alzheimer Disease, Dementia Frontal, Mild Cognitive Impairment
Interventions
EEG scan
Device
Lead sponsor
Metabolic Therapy Inc.
Other
Eligibility
60 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Jul 23, 2026, 9:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise Training and Cognitive Function in Kidney Disease

NCT03197038
View directory record Official record
Conditions
Cognitive Function, Preclinical, Chronic Kidney Diseases, Older Adults
Interventions
Partially supervised home-based walking exercise, Control
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Jul 23, 2026, 9:48 PM EDT
Recruiting Phase 2 Interventional

Alzheimer's Tau Platform: Master Protocol

NCT06957418
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
Interventions
AADvac1, Tau2
Drug
Lead sponsor
Paul S. Aisen
Other
Eligibility
50 Years to 80 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 9:48 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension

NCT04937959
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Jul 23, 2026, 9:48 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PET Changes in Alzheimer's Disease (AD)

NCT00094913
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
20 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2009 · Synced Jul 23, 2026, 9:48 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

NCT05881239
View directory record Official record
Conditions
Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, Healthy Aging
Interventions
AROMHA Brain Health Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 23, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atlas of Retinal Imaging in Alzheimer's Study

NCT03862222
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
Other · Diagnostic Test · Genetic
Lead sponsor
University of Rhode Island
Other
Eligibility
55 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 23, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognitive Detection of Preclinical AD: Validation Using Biomarkers

NCT02616679
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jul 23, 2026, 9:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory

NCT04294888
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Aging
Interventions
repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 23, 2026, 9:48 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

NCT04951284
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Jul 23, 2026, 9:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

TMS for Cognitive Decline in Aging and Preclinical AD

NCT06956300
View directory record Official record
Conditions
Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
Interventions
Active rTMS, Sham rTMS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 23, 2026, 9:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

NCT05026866
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
198
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 23, 2026, 9:48 PM EDT
Completed No phase listed Observational

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

NCT04733989
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jul 23, 2026, 9:48 PM EDT